津力达颗粒联合那格列奈治疗2型糖尿病的临床研究  

Clinical study on Jinlida Granules combined with nateglinide in treatment of type 2 diabetes

作　　者：范慧洁[1] 孙晓菲[1] 殷璐[1] 杨雪[1] 董其娟 FAN Hui-jie;SUN Xiao-fei;YIN Lu;YANG Xue;DONG Qi-juan(Department of Endocrinology and Metabolism,Zhengzhou People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州人民医院内分泌代谢科,河南郑州450000

出　　处：《现代药物与临床》2021年第2期269-273,共5页Drugs & Clinic

基　　金：河南省科技攻关项目(182102310224)。

摘　　要：目的探讨津力达颗粒联合那格列奈治疗2型糖尿病的临床疗效。方法选取2017年4月—2019年5月在郑州人民医院治疗的2型糖尿病患者128例,随机分为对照组和治疗组,每组各64例。对照组餐前口服那格列奈片,120 mg/次,3次/d。治疗组在对照组的基础上口服津力达颗粒,1袋/次,3次/d;两组患者均治疗8周。观察两组患者临床疗效,比较治疗前后两组患者空腹血糖(FPG)、餐后两小时血糖(2 h PG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、三酰甘油(TG)、高密度脂质蛋白(HDL-C)、低密度脂质蛋白(LDL-C)、白细胞介素6(IL-6)、丙二醇(MDA)、超氧化物歧化酶(SOD)、高敏C反应蛋白(hs-CRP)、胰岛素抵抗指数(HOMA-IR)、胰岛素β细胞指数(HOMA-β)。结果治疗后,治疗组总有效率为96.88%,高于对照组总有效率的76.56%(P<0.05)。治疗后,两组FPG、2 h PG、Hb A1c、TC、TG、LDL-C、IL-6、MDA、hs-CRP、HOMA-IR均显著降低,但HDL-C、SOD、HOMA-β显著升高(P<0.05)。治疗后,治疗组患者FPG、2h PG、HbA1c、TC、TG、LDL-C、IL-6、MDA、hs-CRP、HOMA-IR指标均显著低于对照组患者(P<0.05),但HDL-C、SOD、HOMA-β指标显著高于对照组(P<0.05)。结论津力达颗粒联合那格列奈治疗2型糖尿病能有效降低血糖,改善临床症状、血脂与胰腺β细胞水平,药物不良反应较少。Objective To explore the clinical effect of Jinlida Granules combined with nateglinide in treatment of type 2 diabetes. Methods Patients(128) with type 2 diabetes in Zhengzhou People’s Hospital from April 2017 to May 2019 were randomly divided into control and treatment groups, and each group had 64 cases. Patients in the control group were po administered with Nateglinide Tablets, 120 mg/time, three times daily. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the FPG, 2 h PG, HbA1c, TC, TG, HDL-C, LDL-C, IL-6, MDA, SOD, hs-CRP, HOMA-IR, and HOMA-β in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 96.88%, which was higher than 76.56% of the control group(P < 0.05). After treatment, FPG, 2 h PG, HbA1c, TC, TG, LDL-C, IL-6, MDA, hs-CRP and HOMA-IR in two groups were significantly decreased, but HDL-C, SOD, and HOMA-β were significantly increased(P < 0.05). After treatment, FPG, 2 h PG, HbA1 c, TC, TG, LDL-C, IL-6, MDA, hs-CRP and HOMA-IR in the treatment group were significantly lower than those in the control group, while the indexes of HDL-C, SOD, and HOMA-β in the treatment group were significantly higher than those in the control group(P < 0.05). Conclusion Jinlida Granules combined with nateglinide in the treatment of type 2 diabetes can effectively reduce blood glucose, improve clinical symptoms, blood lipids and pancreatic β-cell levels, and have less adverse drug reactions.

关 键 词：津力达颗粒 那格列奈怕 2型糖尿病 空腹血糖 糖化血红蛋白 低密度脂质蛋白 胰岛素β细胞指数 

分 类 号：R977[医药卫生—药品]